Intezyne is a clinical-stage company with an extensive portfolio of product candidates that may offer physicians and patients significant advances in treating a wide variety of tumors.

Latest News

 

Spotlight

IT-139
Intezyne's IT-139 targets GRP78, a crucial factor in tumor chemoresistance.

 

IVECT™ Method

Intezyne, Inc. believes the IVECT Method is a unique and remarkably safe platform that has the potential to raise the bar in terms of what patients and oncologists can expect from chemotherapy.